Drug General Information
Drug ID
Former ID
Drug Name
Fiblast; Fiblast (TN); Trafermin (genetical recombination); Trafermin (USAN/INN); Trafermin (genetical recombination) (JAN)
Indication Periodontitis [ICD-11: DA0C; ICD-10: K05.4; ICD-9: 523.5] Phase 3 [1]
Johnson & Johnson Licensee; Kaken Pharmaceutical
CAS Number
CAS 131094-16-1
PubChem Substance ID
Target and Pathway
Target(s) Fibroblast growth factor receptor 2 (FGFR2) Target Info Activator [1]
KEGG Pathway MAPK signaling pathway
Ras signaling pathway
Rap1 signaling pathway
PI3K-Akt signaling pathway
Signaling pathways regulating pluripotency of stem cells
Regulation of actin cytoskeleton
Pathways in cancer
Prostate cancer
Central carbon metabolism in cancer
NetPath Pathway IL1 Signaling Pathway
Panther Pathway FGF signaling pathway
Pathway Interaction Database FGF signaling pathway
Reactome Activated point mutants of FGFR2
WikiPathways Regulation of Actin Cytoskeleton
Ectoderm Differentiation
Hair Follicle Development: Organogenesis (Part 2 of 3)
Hair Follicle Development: Induction (Part 1 of 3)
Cardiac Hypertrophic Response
Signaling Pathways in Glioblastoma
Neural Crest Differentiation
Signaling by FGFR
MicroRNAs in cardiomyocyte hypertrophy
REF 1 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.